Clinical trials: Left Ventricular Thrombus
Cryptogenic Ischemic Stroke
Cardiac Assessment for Thrombus Detection in the Heart Using Advanced Imaging (MRI, CT) in ESUS With Left Ventricular Disease
The CATCH ME study is a prospective, multicenter, observational, no-profit study aimed at improving embolic risk stratification in patients with embolic stroke of undetermined source (ESUS), particularly in those with left…
- Trial name
- CATCH ME (NCT07298122)
- Where
- Italy
- Volunteers
- 125 people
- Sponsor
- Niguarda Hospital
Left Sided Heart Failure, Left Ventricular Assist Device
Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial
This study evaluates two different methods for monitoring a patient's anti-clotting [heparin] therapy after they receive a heart pump implant [left ventricular assist device -LVAD].
- Conditions
- Left Sided Heart Failure, Left Ventricular Assist Device, Anticoagulant Therapy, Gastro Intestinal Bleeding
- Trial name
- VAD-ANTIX (NCT03143569)
- Testing
- aPTT guided heparin management, Anti-factor Xa guided heparin management
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Myocardial Infarction, Acute, Left Ventricular Thrombus
Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF
APERITIF is a prospective randomized open-label, blinded end-point (PROBE) trial, nested in the ongoing the "FRENCHIE" registry, a French multicenter prospective observational study granted by "ANR-RHU Grand Emprunt", in which…
- Trial name
- APERITIF (NCT05077683)
- Testing
- Rivaroxaban 2.5 MG [Xarelto], DAPT strategy
- Where
- France
- Volunteers
- 560 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cardiomyopathies
Contrast Echocardiography Cost Effectiveness for Left Ventricular Thrombus Assessment
To perform a cost-effectiveness analysis for the routine use of contrast in rest echocardiography in patients with dilated or ischemic cardiomyopathy from the United States healthcare system, provider and payer perspectives.
- Trial name
- NCT02555527
- Where
- United States
- Volunteers
- 500,000 people
- Sponsor
- Duke University
Left Ventricular Thrombus
Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial
The investigators aimed to design this randomized control trial to compare rivaroxaban and apixaban with warfarin in Left ventricular thrombus resolution by Success rate of left ventricular thrombus resolution on follow up…
- Trial name
- WRAP (NCT05973188)
- Testing
- Warfarin, Rivaroxaban 20 MG Oral Tablet, Apixaban 5mg or 2.5mg oral tablet
- Where
- Pakistan
- Volunteers
- 141 people
- Sponsor
- Peshawar Institute of Cardiology
Embolism and Thrombosis, Anticoagulation
Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis
A single-center, open-label, exploratory randomized controlled study is proposed with the following objectives: whether prolonging the duration of anticoagulation to 12 months, compared with 6 months of routine anticoagulation…
- Trial name
- NCT06209892
- Testing
- Extended anticoagulation
- Volunteers
- 220 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Left Ventricular Thrombus, ST Segment Elevation Myocardial Infarction
Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI
The purpose of the study is to assess the safety and efficacy of rivaroxaban-based versus warfarin-based antithrombotic regimens on outcomes of patients with left ventricle thrombosis following acute ST elevation myocardial…
- Trial name
- REWARF-STEMI (NCT05705089)
- Testing
- Rivaroxaban 15 MG, Warfarin
- Where
- 2 sites in Iran
- Volunteers
- 50 people
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
Acute Myocardial Infarction of Anterior Wall, Left Ventricular Thrombus
Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction
The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the…
- Conditions
- Acute Myocardial Infarction of Anterior Wall, Left Ventricular Thrombus, Prophylaxis
- Trial name
- POTAMI (NCT06742567)
- Testing
- Apixaban 2.5 MG PO BID, Control (Standard treatment)
- Where
- Pakistan
- Volunteers
- 472 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
Left Ventricular Thrombus, Thrombosis
The "MyoThrombus" Study
Left ventricular thrombus is a recognised complication of acute myocardial infarction, associated with stroke, recurrent myocardial infarction and adverse cardiac remodelling.
- Conditions
- Left Ventricular Thrombus, Thrombosis, STEMI, Stroke
- Trial name
- NCT04829825
- Testing
- 18F-GP1 PET/MR
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of Edinburgh
Thromboembolism, Hemolysis
Lavare Cycle in Patients Receiving HeartWare Left Ventricular Assist Device
Left ventricular assist device (LVAD) patients remain at risk for pump thrombus and thromboembolic events through multiple mechanisms.
- Conditions
- Thromboembolism, Hemolysis, Stroke
- Trial name
- NCT04199793
- Testing
- Lavare On, Lavare Off
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Vanderbilt University Medical Center
Thrombus, Myocardial Infarction
Diagnostic Utility of Contrast Echocardiography for Detection of LV Thrombi Post ST Elevation Myocardial Infarction
This is a cross-sectional study of post myocardial infarction patients which is designed to determine the prevalence of left ventricular thrombi (blood clots) using non-contrast echocardiography and to compare this with the…
- Trial name
- NCT00539045
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Apical Thrombus Formation, Acute Myocardial Infarction
Implication of Left veNtricle Vortex Flow Guided aNticOagulation Therapy for preVenting Apical Thrombus Formation In Patients With Acute myOcardial infarctioN: Multicenter Prospective Randomized Clinical Trial; INNOVATION Study
Implication of left veNtricle vortex flow guided aNticOagulation therapy for preVenting Apical Thrombus formation In patients with acute myOcardial infarctioN: Multicenter Prospective Randomized Clinical Trial; INNOVATION study
- Trial name
- NCT01869998
- Where
- South Korea
- Volunteers
- 111 people
- Sponsor
- Yonsei University
Left Ventricular Thrombus, Myocardial Infarction
Anticoagulation in Post MI LV Thrombus Trial in Nepal
Introduction: The prevalence of left ventricular(LV) thrombus after acute myocardial infarction has decreased with thrombolysis and primary angioplasty intervention worldwide.
- Trial name
- WaRMIN (NCT05794399)
- Testing
- Rivaroxaban, Warfarin
- Where
- Nepal
- Volunteers
- 196 people
- Sponsor
- Shahid Gangalal National Heart Centre
Acute Coronary Syndrome, Left Ventricular Thrombus
Rivaroxaban in Left Ventricular Thrombus
The left ventricular (LV) thrombus is an important complication of myocardial infarction (MI) and vitamin K antagonist (VKA) is the current recommended management therapy for these patients.
- Trial name
- NCT04970576
- Testing
- Rivaroxaban, Warfarin
- Where
- Pakistan
- Volunteers
- 261 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
LVAD (Left Ventricular Assist Device) Thrombosis
DOT HeartMate 3 Study
A prospective, single-center, randomized controlled trial of the feasibility and safety of apixaban in HeartMate 3 patients.
- Trial name
- NCT04974684
- Testing
- HeartMate 3, Apixaban
- Where
- Czechia
- Volunteers
- 45 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Ventricular Thrombosis Mural Following Myocardial Infarction
LV Thrombus After Acute AMI: A Randomized Controlled Trial
Left Ventricular (LV) thrombus formation is witnessed in at least 10% of patients with ST segment elevation myocardial infarction (STEMI).
- Trial name
- NCT01556659
- Testing
- Absence of vitamin K antagonist
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure
SWITCH: Apixaban vs Vitamin K in HM3
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced…
- Conditions
- LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure, Bleeding, Thrombosis; Artery
- Trial name
- NCT07471139
- Testing
- Warfarin, Apixaban
- Volunteers
- 460 people
- Sponsor
- Columbia University
ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus
Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)
Left ventricular thrombus is a common complication subsequent to ST-segment elevation myocardial infarction (STEMI) that related to increased embolic events.
- Trial name
- NCT03786757
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
Bleeding, Clot Blood
Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device
Heart failure is a world epidemic. LVADs are increasingly used as they have demonstrated improved survival rates compared to optimal medical management.
- Trial name
- NCT06655376
- Testing
- Aspirin, Warfarin
- Where
- 3 sites in United States
- Volunteers
- 128 people
- Sponsor
- Columbia University
Thrombosis, Bleeding
Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device (LVAD)
Patients with severe heart failure supported by left ventricular assist device (LVAD) require adequate long-term anticoagulant therapy.
- Trial name
- NCT02872649
- Testing
- Dabigatran, Phenprocoumon
- Where
- Austria
- Volunteers
- 16 people
- Sponsor
- Daniel Zimpfer, MD